根据早前公布的战略融资协议,生物医药公司Orchestra BioMed(简称OBIO)已成功获得其合作伙伴Ligand Pharmaceuticals(简称LGND)提供的1500万美元投资。
此次注资标志着双方战略合作进入实质性阶段,资金将用于加速Orchestra BioMed核心创新疗法的研发与商业化进程。该笔投资遵循了既定的协议条款,体现了Ligand对Orchestra BioMed技术平台与长期增长潜力的持续信心。
根据早前公布的战略融资协议,生物医药公司Orchestra BioMed(简称OBIO)已成功获得其合作伙伴Ligand Pharmaceuticals(简称LGND)提供的1500万美元投资。
此次注资标志着双方战略合作进入实质性阶段,资金将用于加速Orchestra BioMed核心创新疗法的研发与商业化进程。该笔投资遵循了既定的协议条款,体现了Ligand对Orchestra BioMed技术平台与长期增长潜力的持续信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.